S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
S&P 500   4,567.80 (+0.38%)
DOW   35,950.89 (+1.47%)
QQQ   388.83 (-0.25%)
AAPL   189.95 (+0.31%)
MSFT   378.91 (+0.02%)
META   327.15 (-1.52%)
GOOGL   132.53 (-1.82%)
AMZN   146.09 (-0.16%)
TSLA   240.08 (-1.66%)
NVDA   467.70 (-2.85%)
NIO   7.28 (+1.39%)
BABA   74.86 (+0.25%)
AMD   121.16 (-2.17%)
T   16.57 (+1.66%)
F   10.28 (-2.93%)
MU   76.12 (-0.74%)
CGC   0.56 (+0.00%)
GE   121.74 (+2.42%)
DIS   92.69 (+0.21%)
AMC   6.65 (-7.39%)
PFE   30.44 (+1.20%)
PYPL   57.61 (-0.62%)
XOM   102.80 (+0.45%)
Most-Upgraded StocksMost-Upgraded

Neurocrine Biosciences (NBIX) Earnings Date, Estimates & Call Transcripts

$116.59
+3.05 (+2.69%)
(As of 11/30/2023 ET)
Compare
Today's Range
$114.01
▼
$117.09
50-Day Range
$106.07
▼
$116.68
52-Week Range
$89.04
▼
$129.29
Volume
1.35 million shs
Average Volume
742,197 shs
Market Capitalization
$11.45 billion
P/E Ratio
62.68
Dividend Yield
N/A
Price Target
$131.46
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Feb. 5Estimated
Actual EPS
(Oct. 31)
$0.82 Missed By -$0.09
Consensus EPS
(Oct. 31)
$0.91
Read Call Transcript
Listen to Call
Latest SEC 10-Q Filing
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

NBIX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

NBIX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Neurocrine Biosciences Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20235$0.03$0.72$0.54 
Q2 20236$0.58$1.00$0.83 
Q3 20237$0.83$1.16$1.01 
Q4 20235$0.87$1.37$1.18 
FY 202323$2.31$4.25$3.56 
Q1 20242$0.87$1.33$1.10 
Q2 20242$1.02$1.57$1.30 
Q3 20242$1.16$1.70$1.43 
Q4 20242$1.35$1.96$1.66 
FY 20248$4.40$6.56 $5.48

NBIX Earnings Date and Information

Neurocrine Biosciences last posted its quarterly earnings results on October 31st, 2023. The reported $0.82 earnings per share for the quarter, missing analysts' consensus estimates of $0.91 by $0.09. The firm had revenue of $498.80 million for the quarter, compared to the consensus estimate of $479.09 million. Its quarterly revenue was up 28.6% compared to the same quarter last year. Neurocrine Biosciences has generated $1.86 earnings per share over the last year ($1.86 diluted earnings per share) and currently has a price-to-earnings ratio of 62.7. Earnings for Neurocrine Biosciences are expected to grow by 119.63% in the coming year, from $2.14 to $4.70 per share. Neurocrine Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 5th, 2024 based off prior year's report dates.

Neurocrine Biosciences Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/5/2024
Estimated)		------- 
10/31/2023Q3 2023$0.91$0.82($0.09)$0.82$479.09 million$498.80 million      
8/1/2023Q2 2023$0.77$0.95+$0.18$0.95$448.29 million$452.70 million
5/3/2023Q1 2023$0.26($0.79)($1.05)($0.79)$412.96 million$420.40 million
2/6/2023Q4 2022$1.15$1.24+$0.09$0.88$408.96 million$412.00 million    
11/1/2022Q3 2022$0.84$0.69($0.15)$0.69$378.05 million$387.90 million
8/4/2022Q2 2022$0.56($0.18)($0.74)($0.18)$340.62 million$378.20 million
5/4/2022Q1 2022$0.33$0.14($0.19)$0.14$304.07 million$310.60 million      
2/11/2022Q4 2021$0.61($0.08)($0.69)($0.08)$317.72 million$312.00 million    
11/1/2021Q3 2021$0.51$0.23($0.28)$0.23$297.02 million$296.00 million    
8/2/2021Q2 2021$0.52$0.43($0.09)$0.43$274.47 million$288.90 million    
5/4/2021Q1 2021$0.47$0.33($0.14)$0.33$247.81 million$236.60 million    
2/3/2021Q4 2020$0.59$3.58+$2.99$3.58$260.43 million$247.90 million  












Neurocrine Biosciences Earnings - Frequently Asked Questions

When is Neurocrine Biosciences's earnings date?

Neurocrine Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 5th, 2024 based off last year's report dates. Learn more on NBIX's earnings history.

Did Neurocrine Biosciences beat their earnings estimates last quarter?

In the previous quarter, Neurocrine Biosciences (NASDAQ:NBIX) missed the analysts' consensus estimate of $0.91 by $0.09 with a reported earnings per share (EPS) of $0.82. Learn more on analysts' earnings estimate vs. NBIX's actual earnings.

How can I listen to Neurocrine Biosciences's earnings conference call?

The conference call for Neurocrine Biosciences's latest earnings report can be listened to online. Listen to Conference Call

How can I read Neurocrine Biosciences's conference call transcript?

The conference call transcript for Neurocrine Biosciences's latest earnings report can be read online. Read Transcript

How can I view Neurocrine Biosciences's earnings report?

Neurocrine Biosciences's earnings report can be found in their filing with the SEC. View SEC filing

How much revenue does Neurocrine Biosciences generate each year?

Neurocrine Biosciences (NASDAQ:NBIX) has a recorded annual revenue of $1.49 billion.

How much profit does Neurocrine Biosciences generate each year?

Neurocrine Biosciences (NASDAQ:NBIX) has a recorded net income of $154.50 million. NBIX has generated $1.86 earnings per share over the last four quarters.

What is Neurocrine Biosciences's price-to-earnings ratio?

Neurocrine Biosciences (NASDAQ:NBIX) has a trailing price-to-earnings ratio of 62.68 and a forward price-to-earnings ratio of 54.48. The price/earnings-to-growth ratio is 1.06.

What is Neurocrine Biosciences's EPS forecast for next year?

Neurocrine Biosciences's earnings are expected to grow from $2.14 per share to $4.70 per share in the next year, which is a 119.63% increase.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:NBIX) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -